A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

(2009) A. J. Tevaarwerk et al.   CLINICAL CANCER RESEARCH

Activity of 2 methoxyestradiol (Panzem ® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial

(2009) Daniela Matei et al.   GYNECOLOGIC ONCOLOGY

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

(2008) Arkadiusz Z. Dudek et al.   CANCER

Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis

(2008) Christian Eichelberg et al.   EUROPEAN UROLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy

(2007) Ila Tamaskar et al.   JOURNAL OF UROLOGY